Overview

LEAC-102 for Advanced Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination with FOLFOX + Bevacizumab/Cetuximab in Subjects with Advanced Colorectal Cancer

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Taiwan Leader Biotech Corp.

Treatments:

Bevacizumab
Cetuximab
Fluorouracil
Oxaliplatin